Virtu Financial (VIRT) Q3 2025 Earnings Transcript

Bausch + Lomb reported Q3 revenue of $1.281 billion, up 6% year over year, with adjusted EBITDA up 7% to $243 million and margin expanding 400 bps sequentially to 19%. The company maintained 2025 revenue guidance at $5.05 billion-$5.15 billion but raised the low end of adjusted EBITDA guidance to $870 million from $860 million, citing broad-based strength in Vision Care and Pharma. Key growth drivers included Miebo revenue of $84 million (+71% YoY), Xiidra revenue of $87 million, and contact lens revenue up 6%, while management said tariffs should be fully offset in 2025.

Analysis

BLCO is transitioning from a launch-led story to an operating-leverage story, and that changes the stock’s factor exposure. The key second-order effect is that management is signaling it can keep funding innovation while still driving SG&A down as a percent of sales; if that holds, the market will need to re-rate this from a “pipeline expense” multiple toward a durable growth-and-cash-conversion multiple. The better free cash flow print matters less as a single quarter and more because it gives the company room to self-fund deleveraging without choking off launch spend.

The biggest competitive implication is in dry eye, where combination therapy can enlarge the market rather than just redistribute share. That is bullish for the incumbent leader because it makes the category less winner-take-all and more regimen-based, which tends to favor the company with the broadest field force, payer access, and default brand presence. A subtler read is that the strongest near-term risk is not launch competition but execution consistency across multiple channels; if any one of consumer, contact lens, or surgical stumbles, the margin narrative can stall quickly because the valuation is now leaning on broad-based discipline, not just top-line growth.

The surgical rebound is more important than the headline suggests because it reduces the probability that the recall becomes a permanent share leak. If premium IOL volumes normalize into Q4 and early 2026, it creates an earnings lever with better gross margin than the rest of the portfolio, which could be a visible catalyst around the next investor day. The contrarian concern is that the market may be overestimating how much of the margin expansion is structural versus mix/timing; if tariff offsets slip or China softness broadens, the company may have to choose between protecting growth and defending EBITDA, which would compress the multiple quickly.

Key Decisions for Investors

• Long BLCO into the Nov. 13 investor day; target a 3-6 month horizon for a multiple re-rate if management shows a credible 2026 margin bridge. Best risk/reward is on any post-event pullback rather than chasing strength.
• Use a BLCO call spread (e.g., 6-9 month tenor) to express upside from SG&A leverage and surgical normalization while capping premium outlay; attractive if you believe free cash flow inflects faster than consensus.
• Pair trade: long BLCO / short a higher-quality med-tech or eye-care peer with less operating leverage if you want to isolate execution upside. This works best if investor day confirms the company can grow and delever simultaneously.
• Fade the knee-jerk bullishness if gross margin fails to expand again next quarter; that would indicate the 400 bps EBITDA margin step-up was partly timing-driven rather than durable. In that case, trim longs and wait for better entry.
• Keep a tactical eye on BABA-related China risk as an indirect hedge: if China consumer softness worsens, it is a warning sign for BLCO’s contact lens and OTC demand mix, making the stock more vulnerable on the next guidance update.